MediWound’s NexoBrid Triumphs in Burn Care Study
Company Announcements

MediWound’s NexoBrid Triumphs in Burn Care Study

Mediwound (MDWD) has released an update.

MediWound Ltd. reported positive outcomes from the NEXT protocol, showcasing the safety and effectiveness of their NexoBrid product in removing eschar and substantially reducing surgical procedures for burn patients. The program has verified NexoBrid’s rapid debridement capability in both adults and children, with the vast majority achieving complete eschar removal without the need for surgical excision. These results support NexoBrid’s integration into standard burn care protocols.

For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMediWound announces Phase II study evaluating EscharEx
TheFlyMediWound files to sell 1.45M ordinary shares for holders
TipRanks Auto-Generated NewsdeskMediWound’s NexoBrid Gains FDA Pediatric Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App